Institute for Soldier Nanotechnologies, Massachusetts Institute of Technology, Cambridge; Department of Materials Science, University of Texas at Dallas, Richardson.
Institute for Soldier Nanotechnologies, Massachusetts Institute of Technology, Cambridge.
Mayo Clin Proc. 2015 Jan;90(1):93-108. doi: 10.1016/j.mayocp.2014.10.003. Epub 2014 Dec 4.
Miniaturization of devices to micrometer and nanometer scales, combined with the use of biocompatible and functional materials, has created new opportunities for the implementation of drug delivery systems. Advances in biomedical microdevices for controlled drug delivery platforms promise a new generation of capabilities for the treatment of acute conditions and chronic illnesses, which require high adherence to treatment, in which temporal control over the pharmacokinetic profiles is critical. In addition, clinical conditions that require a combination of drugs with specific pharmacodynamic profiles and local delivery will benefit from drug delivery microdevices. This review provides a summary of various clinical applications for state-of-the-art controlled drug delivery microdevices, including cancer, endocrine and ocular disorders, and acute conditions such as hemorrhagic shock. Regulatory considerations for clinical translation of drug delivery microdevices are also discussed. Drug delivery microdevices promise a remarkable gain in clinical outcomes and a substantial social impact. A review of articles covering the field of microdevices for drug delivery was performed between January 1, 1990, and January 1, 2014, using PubMed as a search engine.
器件的微型化和纳米化，结合生物相容性和功能材料的使用，为药物输送系统的实施创造了新的机会。用于控制药物输送平台的生物医学微器件的进步有望为治疗急性病和慢性病带来新一代的能力，这些疾病需要高度的治疗依从性，其中对药代动力学特征的时间控制至关重要。此外，需要将具有特定药效学特征的药物与局部输送相结合的临床病症将受益于药物输送微器件。本文综述了最先进的控制药物输送微器件的各种临床应用，包括癌症、内分泌和眼部疾病，以及急性病症如出血性休克。还讨论了药物输送微器件临床转化的监管考虑因素。药物输送微器件有望在临床结果方面取得显著改善，并产生重大的社会影响。对 1990 年 1 月 1 日至 2014 年 1 月 1 日期间涵盖药物输送微器件领域的文章进行了综述，使用 PubMed 作为搜索引擎。
